Economiic Home Method Watch Market RSI Search

Connect Biopharma Holdings Limited CNTB

Sector:

Healthcare

Industry:

Biotechnology

Description:

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Connect Biopharma Holdings Limited website

Recent Quarter:

2024-09-05

Upcoming Quarter:

N/A

Annual Reports

Date2024-04-16
Revenue 0
Net Income -59,503,000
EPS -1.08
Basic Shares 55,067,021
Diluted Shares 55,067,000
Report Link
Date2023-04-11
Revenue 0
Net Income -116,415,196
EPS -14.5
Basic Shares 55,044,000
Diluted Shares 55,044,000
Report Link
Date2022-03-31
Revenue 0
Net Income -205,205,345
EPS -25
Basic Shares 52,272,960
Diluted Shares 52,272,960
Report Link
Date2020-12-31
Revenue 0
Net Income -120,303,936
EPS -14.45
Basic Shares 53,941,675
Diluted Shares 53,941,675
Report Link
Date2019-12-31
Revenue 0
Net Income -24,021,147
EPS -3.02
Basic Shares 55,816,675
Diluted Shares 55,816,675
Report Link

Annual Ratios

Date2023-12-31
PE -1.09
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.41
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -1.31
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -8.29
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-12-31
PE -42.96
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2018-12-31
PE 0.00
Dividend Yield 0.00
Payout Ratio: 0.000%

Quarterly Reports

Date2024-06-30
Revenue 12,058,000
Net Income 3,824,500
EPS 0.0694
Basic Shares 55,143,825
Diluted Shares 55,554,249
Report Link
Date2024-03-31
Revenue 12,058,000
Net Income 3,824,500
EPS 0.0694
Basic Shares 55,143,825
Diluted Shares 55,554,249
Report Link
Date2024-04-16
Revenue 0
Net Income -14,805.583
EPS -0.27
Basic Shares 55,082,000
Diluted Shares 55,082,000
Report Link
Date2023-09-30
Revenue 0
Net Income -15,226.927
EPS -0.28
Basic Shares 55,082,000
Diluted Shares 55,082,000
Report Link
Date2023-06-30
Revenue 0
Net Income -30,581,163
EPS -0.56
Basic Shares 55,051,351
Diluted Shares 55,051,351
Report Link
Date2023-03-31
Revenue 0
Net Income -15,431.8,830,411
EPS -0.28
Basic Shares 55,051,000
Diluted Shares 55,051,000
Report Link
Date2023-04-11
Revenue 0
Net Income -56,678,631
EPS -1.03
Basic Shares 55,022,777
Diluted Shares 55,022,777
Report Link
Date2022-09-30
Revenue 0
Net Income -30,843.077
EPS -0.56
Basic Shares 55,023,000
Diluted Shares 55,023,000
Report Link
Date2022-06-30
Revenue 0
Net Income -61,918,783
EPS -1.12
Basic Shares 55,064,947
Diluted Shares 55,064,947
Report Link
Date2022-03-31
Revenue 0
Net Income -31,643.7,718,767
EPS -0.57
Basic Shares 55,064,000
Diluted Shares 55,064,000
Report Link
Date2022-03-31
Revenue 0
Net Income -56,652,416
EPS -1.05
Basic Shares 53,735,021
Diluted Shares 53,735,021
Report Link
Date2021-08-31
Revenue 0
Net Income -28,248.899,024
EPS -0.49
Basic Shares 57,418,000
Diluted Shares 57,418,000
Report Link
Date2021-08-31
Revenue 0
Net Income -145,709,216
EPS -3.1
Basic Shares 46,935,542
Diluted Shares 46,935,542
Report Link
Date2021-03-31
Revenue 0
Net Income -71,917.6,650,156
EPS -1.53
Basic Shares 46,935,000
Diluted Shares 46,935,000
Report Link
Date2020-12-31
Revenue 0
Net Income -53,924.599,419,499,995
EPS -3.16
Basic Shares 17,089,000
Diluted Shares 17,089,000
Report Link
Date2020-09-30
Revenue 0
Net Income -51,841.5,045,311
EPS -3.03
Basic Shares 17,089,000
Diluted Shares 17,089,000
Report Link
Date2020-06-30
Revenue 0
Net Income -5,322.1,286,523
EPS -0.31
Basic Shares 17,090,000
Diluted Shares 17,090,000
Report Link
Date2020-03-31
Revenue 0
Net Income -5,309.3,540,402
EPS -0.31
Basic Shares 17,090,000
Diluted Shares 17,090,000
Report Link

Quarterly Ratios

Date2024-06-30
PE 5.19
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2024-03-31
PE 7.93
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-12-31
PE -1097.50
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-09-30
PE -740.66
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-06-30
PE -0.51
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-03-31
PE -891.84
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.21
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-09-30
PE -575.33
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-06-30
PE -0.19
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-03-31
PE -1313.79
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -1.22
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-09-30
PE -12312.32
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-06-30
PE -1.57
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-03-31
PE -3018.37
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE -1464.90
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-09-30
PE -1523.76
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-06-30
PE -14843.41
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-03-31
PE -14879.12
Dividend Yield 0.00
Payout Ratio: 0.000%

RSI:

49.68

Price:

$0.97

Market Cap:

53,872,681

EPS TTM:

-0.41

PE Ratio:

7.60

PEPSG:

NaN

Fwd PE:

NaN

Volume:

30,532

2 Year Price Change

1.318

Index 2 Year Price Change

1.497

5 Year Price Change

No Price 5 Years Ago

Index 5 Year Price Change

1.905
PESPG: Growth Rate of EPS projected to next quarter and 6 months trailing. Lower is better to help calculate nexts quarters PE Ratio today. Diluted shares effects the EPS reported and makes calculation show as extremely poor expected growth.

Revenue

Net Income

EPS

Shares

News

Press Releases

Notable Earnings

Please select an option: